Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Retaane “Approvable” For Macular Degeneration; Alcon Plans July Meeting With FDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Alcon expects to meet with FDA in July to discuss a May 23 "approvable" letter for its wet age-related macular degeneration agent Retaane (anecortave acetate suspension)

You may also be interested in...

Genentech Lucentis priority review

Genentech's BLA for its wet age-related macular degeneration treatment Lucentis (ranibizumab) is granted a priority review at FDA, giving the VEGF antibody a June 29 user fee goal date. Genentech's submission includes a head-to-head trial with Novartis/QLT's photodynamic therapy Visudyne (verteporfin). Genentech has referred to Lucentis as the first wet AMD treatment to show a clinical benefit over PDT in a head-to-head study setting (1Pharmaceutical Approvals Monthly June 2005, p. 12). In conjunction with the priority review designation, Genentech announced preliminary, two-year data from its Phase III MARINA study showing improvement at two years...

Genentech’s Lucentis BLA Will Not Include Data Supporting Dosing Advantage

FDA's decision to deny Genentech fast-track status for Lucentis (ranibizumab) means that the initial submission for the wet age-related macular degeneration therapy, slated for December, will not include data supporting a dosing advantage

Miravant Photrex confirmatory trial begins

Miravant is initiating a 600-patient confirmatory trial of its macular degeneration therapy Photrex (rostaporfin, SnET2), the firm says March 10. The FDA-requested trial's design, reviewed under a special protocol assessment, will evaluate a range of patients with wet age-related macular degeneration, including both classic and occult lesions" (1Pharmaceutical Approvals Monthly February 2005, p. 16)...





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts